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INTRODUCTION
Sepsis and septic shock are life-threat-
ening medical conditions, characterized
by uncontrolled or overwhelming sys-
temic inflammatory response to an infec-
tion and accounts for more than 750,000
cases annually in the United States (1).
Despite significant advances and exten-
sive therapeutic approaches, sepsis re-
mains a major health concern and leading
cause of high mortality worldwide (2–4).
Human and animal studies have demon-
strated that progressive multiple organ
failure is the most common cause of death
following sepsis, with the lungs usually
representing the first organ to fail (5). Pre-
disposition of the immune response has
been shown to be critical in the develop-
ment of an exaggerated inflammatory re-
action and ensuing acute lung injury
(ALI) (6). The clinical pathology of ALI in-
cludes increased vascular permeability, in-
flammation, oxidative stress, apoptosis,
pulmonary edema and the accumulation
of activated neutrophil in lung tissue and
eventually cell death (7–11).
AMP-activated protein kinase (AMPK)
is a serine/threonine kinase that functions
as an energy sensing enzyme and is acti-
vated in response to an increase of the
AMP/ATP ratio during hypoxia, glucose
deprivation, heat shock or reduction in
mitochondrial oxidative phosphorylation
(12,13). AMPK is a heterotrimeric complex
consisting of three subunits, α catalytic
subunit and regulatory β and γ subunits
(14). Two isoforms have been identified
for both α subunit (α1 and α2) and β sub-
unit (β1 and β2), and three isoforms have
been reported for the γ subunit (γ1, γ2 and
γ3) (14). Most recently, several reports in-
dicate that the function of AMPK is not
only restricted to the maintenance of en-
ergy metabolism, but also to coordination
of several housekeeping mechanisms and
involvement in modulating oxidative
stress and inflammatory mediators
(15–18). An adenosine monophosphate
analog, 5-aminoimidazole-4-carboxamide
ribonucleotide (AICAR), has been used as
a pharmacological activator to upregulate
AMPK activity (19). Administering
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AICAR has been shown to inhibit inflam-
mation and to alleviate organ injury in ro-
dents (13,20–22).
There is growing evidence that the cen-
tral nervous system (CNS) plays an im-
portant and functionally relevant role in
regulating the inflammatory response.
For example, the vagus nerve and cholin-
ergic pathway have been demonstrated
to be involved in modulating proinflam-
matory cytokine-induced injury locally
and systemically in infectious diseases
(23–26). However, the molecular mecha-
nisms of the CNS in regulating systemic
inflammation are still not well character-
ized. The hypothalamus, a key region in
the CNS, controls several peripheral
physiological activities through a broad
network of hormonal and neuronal com-
munication (27). AMPKα is expressed in
hypothalamic neurons as a fuel sensor
and counteracts energy deficits in the
brain (28). More specifically, the AMPKα1
is primarily cytoplasmic, whereas
AMPKα2 is predominantly nuclear and
plays a role in transcriptional regulation
(29). In addition, the α2 catalytic subunit
is highly expressed in neurons in com-
parison with α1 (30). Thus, we hypothe-
sized that activation of AMPK in the CNS
could attenuate inflammatory responses
and reduce ALI in sepsis.
In this study, we examined the mecha-
nistic and beneficial effect of activating
centrally located AMPK in septic mice
induced by cecal ligation and puncture
(CLP). AICAR administration to the
brain through intracerebroventricular
(ICV) injection attenuated the peripheral
inflammation, as evidenced by decreased
production of cytokines and chemokines,
and reduced lung injury in septic mice.
We also provided the evidence that the
protective effect of AICAR is mediated
though the presence of AMPKα2 in the
brain by using AMPKα2 deficient mice.
MATERIALS AND METHODS
Animals
Male age-matched wild-type C57 BL/6
mice (25-30 g) (Taconic) and AMPKα2
knockout (Prkaa2–/–) mice were obtained
from Benoit Viollet (INSERM) and were
maintained at the Feinstein Institute for
Medical Research (14). They were
housed in a temperature-controlled room
on a 12-h light–dark cycle and fed a stan-
dard mouse diet. All experiments were
performed in accordance with the Na-
tional Institutes of Health guidelines for
use of experimental animals (Guide for
the Care and Use of Laboratory Animals, 8th
edition, 2011), and this study was ap-
proved by the Institutional Animal Care
and Use Committee of the Feinstein In-
stitute for Medical Research.
Intracerebroventricular (ICV) Injection
Stereotactic and surgical materials
were obtained from Stoelting and Hamil-
ton. Animals were lightly anesthetized
with inhalational isoflurane and the head
of the animal was secured on the stereo-
tactic apparatus. A thermal pad was used
to maintain core body temperature dur-
ing the procedure. The head of the ani-
mal was shaved and cleansed with 10%
povidone-iodine wash. A midline inci-
sion was made, extending from the eyes
to the back of the cranium to expose the
bregma. Either 20 ng AICAR (Sigma-
Aldrich) or 2 μL vehicle (normal saline)
was injected into the lateral ventricle
area by using predetermined coordinates
(AP, 0.34 mm from bregma; lateral, 1.0 m;
and vertical, 2.2 mm).
Animal Model of Sepsis
Thirty minutes after ICV injection, the
animal was removed from the stereotactic
apparatus and placed in supine position.
The ventral abdomen was shaved and
cleansed with 10% povidone–iodine wash
and cecal ligation and puncture (CLP) was
performed as previously described (31).
One- to 2-cm midline incision was per-
formed to allow exposure of the cecum
and tightly ligated ~1.0 cm from the tip
with a 3-0 silk suture. A through double
puncture of the cecum was performed
using a 22-gauge needle. A small amount
of feces was expressed from the perforated
sites and returned to the peritoneal cavity.
The laparotomy site was then closed with
6-0 silk suture. Sham-operated animals
underwent the same procedure with the
exception that the cecum was neither lig-
ated nor punctured. The CLP animals sub-
cutaneously received 1 mL isotonic nor-
mal saline immediately after the surgery.
Western Blotting
Hypothalamus and surrounding tissue
were lysed and homogenized in 300 μL
lysis buffer (10 mmol/L Tris-HCL pH 7.5,
120 mmol/L NaCl, 1% NP-40, 1% sodium
deoxycholate and 1% Triton X-100) con-
taining protease and phosphatase inhibitor
cocktails (Roche) using a sonic dismembra-
tor on ice. Samples were centrifuged at
14,000g for 20 min at 4°C, and the super-
natant were collected. Following measure-
ment of sample protein concentration by
Pierce BCA protein assay kit (Pierce
Biotechnology), 60 μg samples were sepa-
rated on 4% to 12% Bis-Tris gradient gels
and transferred to nitrocellulose mem-
branes. Membranes were blocked by incu-
bation with 0.1% casein followed by incu-
bation with primary antibody against
p-AMPKα, t-AMPKα (Cell Signaling), or
β-actin (Sigma-Aldrich). After washing,
membrane was incubated with appropriate
fluorescent secondary antibodies. Bands
were detected using the Odyssey FC Dual-
Mode Imaging system 2800 (LI-COR).
Measurements of Serum Liver
Enzymes and Cytokines
Whole-blood samples were centrifuged
at 4,000g for 12 min to collect serum, which
was then stored at –80°C before use. The
activity of aspartate aminotransferase
(AST) was determined by a commercial
assay kit from Pointe Scientific. Serum
tumor necrosis factor-α (TNF-α), inter-
leukin 1β (IL-1β) and interleukin-6 (IL-6)
levels were determined by an enzyme-
linked immunosorbent assay kit specific
for mouse (BD Biosciences). The assays
were carried out according to the instruc-
tions provided by the manufacturer.
Real-Time Reverse Transcriptase–
Polymerase Chain Reaction (RT-PCR)
Analysis
Total RNA was extracted from lung tis-
sue by TRIzol reagent (Invitrogen) and
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reverse-transcribed in to cDNA by using
murine leukemia virus reverse transcrip-
tase (RT) (Applied Biosystems). A PCR
reaction was carried out in 25 μL final
volume containing 0.08 μmol of each 
forward and reverse primer, 5 μL cDNA,
6.5 μL H2O and 12.5 μL SYBR Green PCR
Master Mix (Applied Biosystems). Am-
plification was conducted in an Applied
Biosystems 7300 real-time PCR machine
under the thermal profile of 50°C for 
2 min and 95°C for 10 min, followed by
45 cycles of 95°C for 15 s and 60°C for 
1 min. The level of mouse β-actin mRNA
was used for normalization and each
specific mRNA was conducted in dupli-
cate. Relative expression of mRNA was
calculated by the 2–ΔΔCt method, and re-
sults were expressed as fold change in
comparison with controls. The sequences
of primers for this study are listed in
Table 1.
Myeloperoxidase (MPO) Activity
Assay
Lung tissues were sonicated in 
50 mmol/L potassium phosphate buffer
containing 0.5% hexadecyl trimethyl 
ammonium bromide. After the centrifuga-
tion, the supernatant was diluted in reac-
tion solution containing o-dianisidine hy-
drochloride and H2O2. The rate of change
in optical density (OD) for 1 min was
measured at 460 nm to calculate MPO ac-
tivity as described previously (32).
Histological Evaluation and Terminal
Deoxynucleotidyl Transferase dUTP
Nick-End Labeling (TUNEL) Staining of
the Lungs
Lung tissues were taken from the
upper and lower lobes 20 h following
CLP and stored in 10% formalin before
being fixed in paraffin. Tissues were then
sectioned to 4-μm cuts and stained with
hematoxylin-eosin. For TUNEL staining,
fluorescence staining was performed
using a commercially available in situ
Cell Death Detection Kit (Roche). The
assay was conducted according to the
manufacturer’s instructions. The nucleus
was stained with propidium iodide. Re-
sults were expressed as the average
number of TUNEL-positive staining cells
per 10 microscopic fields.
Statistical Analysis
All data are expressed as a mean ± SE
(n = 6–8/group) and compared by one-
way analysis of variance (ANOVA) and
the Student-Newman-Keuls (SNK) test.
Differences in values were considered
significant if P < 0.05.
RESULTS
AICAR Activates AMPKα in the Brain of
Septic Mice
We first verified the effect of centrally
administered AICAR on the activation of
AMPKα. At 20 h after CLP, the hypothal-
amus sections of the mice were har-
vested and subjected to Western blot
analysis. The phosphorylated level of
AMPKα in the brain remained un-
changed after CLP, while its level in-
creased by 2.18-fold in the AICAR treat-
ment group in comparison with the
vehicle treated septic mice (Figure 1).
This result indicated that ICV-injection of
IACAR effectively stimulated AMPK ac-
tivity in the brain of septic mice.
AICAR Attenuates Organ Injury and
Systemic Inflammation in Septic Mice
We then examined the effect of AICAR
treatment on the tissue damage and in-
flammatory response in sepsis. At 20 h
after CLP, the serum level of AST, an
organ injury marker, increased by 7.4-fold
in the vehicle, compared with the sham
(Figure 2A). By contrast, AICAR treat-
ment significantly decreased the AST
level by 36.7% as compared with the vehi-
cle group (Figure 2A). Similarly, we also
found significantly increased serum levels
of proinflammatory cytokines, TNF-α
(25.3-fold), IL-1β (24.3-fold) and IL-6 (6.8-
fold) in the vehicle group as compared
with the respective sham groups. Impor-
tantly, AICAR treatment significantly de-
creased the level of TNF-α by 70.5%, IL-1β
by 90.3%, and IL-6 by 42.2% as compared
with the vehicle (Figures 2B–D).
AICAR Ameliorates Lung Damage
and Apoptosis in Septic Mice
The lungs are very vulnerable in sepsis
(33). We examined the lung tissue at 20 h
after CLP with hematoxylin and eosin
staining. As shown in Figure 3, CLP in-
duced severe lung injury shown with sep-
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Table 1. A list of primer sequences used in this study.
Name GenBank Forward Reverse
TNF-α X_02611 AGACCCTCACACTCAGATCATCTTC TTGCTACGACGTGGGCTACA
IL-1β NM_008361 CAGGATGAGGACATGAGCACC CTCTGCAGACTCAAACTCCAC
KC NM_008176 GCTGGGATTCACCTCAAGAA ACAGGTGCCATCAGAGCAGT
MIP-2 NM_009140 CCCTGGTTCAGAAAATCATCCA GCTCCTCCTTTCCAGGTCAGT
β-Actin NM_007393 CGTGAAAAGATGACCCAGATCA TGGTACGACCAGAGGCATACAG
Figure 1. Phosphorylation of AMPK in the
brain. The hypothalamus and surrounding
tissue of sham, vehicle- and AICAR-treated
mice were harvested at 20 h after CLP. The
tissue was lysed and subjected to Western
blotting against phosphorylated (p-
AMPKα) and total AMPK (t-AMPKα). His-
togram shows mean densitometric analy-
sis of bands after normalizing with t-AMPK
and β-actin. Expression in the sham group
is designated as 1 for comparison. Data
are expressed as mean ± SE (n = 6–8 per
group). *P < 0.05 versus sham and #P < 0.05
versus vehicle.
tal thickening, proteinaceous exudate,
pulmonary edema and enhanced inflam-
matory infiltrates as compared with the
sham. By contrast, the severity of lung
damage was ameliorated by AICAR treat-
ment, shown with a better integrity of mi-
croscopic structure as compared with the
vehicle-treated animals (Figure 3).
Apoptosis plays a major role in the
pathogenesis of sepsis-induced organ in-
jury (34). We applied TUNEL assay to ex-
amine the apoptosis in the lungs by im-
munofluorescence. In the vehicle group,
the TUNEL-positive cells (green fluores-
cence) were well detected, while they
were barely observed in the sham (Fig-
ure 4A). On the other hand, the number
of TUNEL-positive cells in the lung tis-
sues of the AICAR-treated mice was re-
duced significantly (63.3%) as compared
with the vehicle group (Figure 4B).
AICAR Suppresses Lung Inflammation
and Neutrophil Infiltration in Septic
Mice
Excessive production of proinflamma-
tory cytokines is one of the important
contributing factors for the lung injury
(35). Lung tissue was harvested at 20 h
after CLP and subjected to RT-PCR and
ELISA analysis. The mRNA level of TNF-α
was increased by 53.1-fold in vehicle-
treated animal as compared with the
sham. Parallel to mRNA expression, we
found increased protein levels of TNF-α
in vehicle-treated animal as compared
with the sham (Figures 5A, B). AICAR
treatments significantly suppressed
mRNA and protein levels of TNF-α by
72.5% and 44.2%, respectively, compared
with the vehicle (Figures 5A, B). Simi-
larly, the mRNA and protein levels of IL-
1β were elevated significantly in the ve-
hicle group as compared the sham, while
their levels were reduced by 76.9% and
47.4%, respectively, compared with the
vehicle (Figures 5C, D).
Chemokines keratinocyte derived-
chemokine (KC) and macrophage inflam-
matory protein-2 (MIP-2) both have been
shown to participate in the pathogenesis
of lung injury (36,37). The mRNA levels
of KC and MIP-2 increased by 748- and
1415-fold, respectively, in the vehicle as
compared with the sham (Figures 6A, B).
By contrast, a significant reduction of KC
mRNA by 76.2% and MIP-2 mRNA by
64.2% was observed in lung tissues of
AICAR-treated mice (Figures 6A, B). We
further measured the myeloperoxidase
activity (MPO) in the lungs to evaluate
the neutrophil infiltration. The MPO ac-
tivity increased by 3.1-fold in vehicle-
treated group as compared with the
sham, while AICAR treatment decreased
the MPO activity by 42.4% as compared
with the vehicle (Figure 6C).
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Figure 2. Alterations in serum levels of organ injury marker and proinflammatory cytokines.
Blood of sham, vehicle- and AICAR-treated mice were harvested at 20 h after CLP for
measuring (A) AST, (B) TNF-α, (C) IL-1β, and (D) IL-6. Data are expressed as mean ± SE (n =
6–8 per group). *P < 0.05 versus sham and #P < 0.05 versus vehicle.
Figure 3. Morphological changes in the lungs. The lung tissues of sham, vehicle- and
AICAR-treated mice were harvested at 20 h after CLP and subjected to histological anal-
ysis with hematoxylin–eosin staining. Representative images of lung histology from n = 6–8
per group. Original magnification 100× (top panels); 200× (bottom panels).
AICAR Activity Is Mediated by
AMPKα2 in the Brain of Septic Mice
To investigate the molecular mechanism
by which AICAR treatment to the CNS at-
tenuated organ injury and inhibited in-
flammation, we undertook a genetic ap-
proach. AMPKα2 is highly expressed in
the neurons of the brain. Thus, we per-
formed the CLP in AMPKα2 knockout
(KO) mice after ICV injection of either ve-
hicle or AICAR as described in the wild-
type (WT) mice. We first measured the
serum AST level and observed its eleva-
tion in the vehicle group of AMPKα2 KO
mice, which was similar to that in the WT
mice (Figure 7A). AICAR treatment only
reduced AST levels by 13.8% without sta-
tistical significance as compared with the
vehicle (Figure 7A). Similarly, there was an
increase in serum levels of TNF-α and IL-
1β in septic AMPKα2 KO mice, however,
AICAR treatment did not significantly
change their levels as compared with the
vehicle (Figures 7B, C).
We also examined the mRNA levels of
proinflammatory cytokines and
chemokines in the lungs by RT-PCR.
There was an increase in mRNA levels of
TNF-α, IL-1β, KC and MIP-2 in the lungs
of vehicle-treated AMPKα2 KO mice as
compared with their respective sham
(Figures 8A–D). However, AICAR-treated
AMPKα2 KO septic mice did not show
any significant changes in the expression
levels of these cytokines and chemokines
as compared with the vehicle-treated
AMPKα2 KO septic mice (Figures 8A–D).
Taken together, these results suggest that
the protective effects of administered ICV
with AICAR in the WT mice may mainly
mediate through AMPKα2-dependent
mechanisms in the brain.
DISCUSSION
Sepsis is the leading cause of death
among critically ill patients and is the
most common risk factor for ALI. Un-
governed inflammation, characterized by
cytokine storm and subsequent neutrophil
sequestration is an underlying component
of sepsis associated organ failure (38).
Thus, elucidation of novel molecular and
cellular pathways that influence the
pathogenesis of sepsis and its associated
complication could provide greater insight
into the mechanisms of disease pathology.
The significance of the brain AMPK
stimulation in regulation of inflammation
in sepsis is not known. We have used a
combination of pharmacological and ge-
netic approaches for the study. First, we
demonstrate that ICV injection of AICAR
markedly increases the phosphorylation
of AMPK in the brain of CLP-induced
septic mice. Such AICAR administration
reduced organ injury and inhibited sys-
temic inflammation. In more specific or-
gans, both the severity of damage and the
induction of apoptosis in the lungs of
septic mice are attenuated by AICAR
treatment, which is associated with a re-
duction of cytokine and chemokine pro-
duction as well as neutrophil infiltration.
On the other hand, AICAR-mediated pro-
tective effect on lowering organ injury
and inflammation in septic WT mice is
diminished in septic AMPKα2 KO mice,
suggesting that brain AMPKα2 may be a
key player to mediate AICAR activity.
Activation of AMPK by systemic ad-
ministration of AICAR has been shown to
suppress inflammatory responses in other
studies. Zhao and coworkers demonstrate
that AICAR reduces the proinflammatory
activity of neutrophils and decreases the
severity of ALI through AMPK activation,
linking to cellular responses to metabolic
stress (13). Escobar et al. demonstrate that
activation of AMPK by AICAR amelio-
rates liver and renal injury in septic mice,
which is associated with a decrease in cir-
culating cytokines and tissue inflamma-
tion (39). In this study, we provide new
evidence of activating the CNS in regulat-
ing the systemic responses. By directly in-
jecting AICAR into the brain, we have ob-
served a significant reduction of serum
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Figure 4. Apoptosis in the lungs after CLP. The lung tissues of sham, vehicle- and AICAR-
treated mice were harvested at 20 h after CLP and subjected to TUNEL assay. (A) Repre-
sentative images of TUNEL staining (green fluorescent) and nuclear counterstaining (red
fluorescent) of lung sections. Original magnification 100×. Scale bar, 50 μm. (B) The num-
ber of apoptotic cells in the lung quantified from TUNEL staining. Data are expressed as
mean ± SE (n = 6–8 per group). *P < 0.05 versus sham and #P < 0.05 versus vehicle.
levels of proinflammatory cytokines TNF-
α, IL-1β and IL-6 in septic mice.
Another important aspect of our study
is to observe an improvement of lung
morphology and inhibition of lung apo-
ptosis in septic mice with central AICAR
injection. As known, lung tissue damage
is observed in 90% of patients dying
from sepsis and its associated complica-
tion (40). The histopathological features
of lung injury in septic mice demon-
strated here are resembled in the clinical
condition of patients with sepsis (41).
Other studies have indicated that apo-
ptosis plays an important role on pro-
gression of sepsis (42,43). Oberholzer and
colleagues suggested that targeting sig-
naling pathways that lead to apoptosis
would represent a new therapeutic target
for the patient with sepsis or other re-
lated clinical conditions (34). By systemic
administration, AICAR has been shown
to decrease the apoptosis in different
cells associated with various disease con-
ditions (44–46). Rossi and Lord describe
that AICAR treatment decreases the neu-
trophil apoptosis through the AMPK ac-
tivation, suggesting an important role of
AMPK in normal function of neutrophils
(45). Similarly, Kim et al. demonstrate
that AICAR reduces the palmitate-in-
duced apoptosis in neuron cells by acti-
vation of AMPK (46).
In addition to inhibiting systemic in-
flammation, central AICAR administra-
tion also decreases local inflammation in
the lungs. We have demonstrated a sig-
nificant decrease in expression of cy-
tokines TNF-α.and IL-1β in the lungs
with AICAR treatment. Moreover, central
AICAR administration also effectively in-
hibits the expression of KC and MIP-2 in
the lungs. It has been reported that ele-
vated expression of KC and MIP-2 po-
tently stimulate neutrophil influx in the
lungs, while suppression of these
chemokines markedly inhibits neutrophil
sequestration in the lungs (47). Consis-
tent with this mechanism, we have de-
tected decreased MPO activity, a marker
for neutrophil infiltration (48). Consid-
ered together, our findings suggest that
activation of the brain AMPK by AICAR
for a protective milieu to the lung in sep-
sis may confer inhibition of the produc-
tion of inflammatory mediators.
We then further identify the specific
target in the CNS for AICAR’s activity in
regulating systemic inflammation. When
comparing the serum levels of AST, TNF-
α and IL-1β in septic AMPKα2 KO mice
between vehicle and AICAR ICV injec-
tions, the beneficial effects of AICAR ob-
served in the septic WT mice are dimin-
ished in the AMPKα2 KO mice.
Moreover, the AICAR’s effect on inhibit-
ing the expression of cytokines and
chemokines in the lungs of the septic WT
mice disappeared in the septic AMPKα2
KO mice. These results clearly indicate
that AMPKα2 in the brain is majorly re-
sponsible for central AICAR stimulation.
As it has been indicated that the CNS can
modulate the systemic inflammation and
cytokines production by: 1) activation of
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Figure 5. Alterations in expression of proinflammatory cytokines in the lungs. The lung tissues
of sham, vehicle- and AICAR-treated mice were harvested at 20 h after CLP for measuring
the mRNA levels of (A) TNF-α and (C) IL-1β by real-time RT-PCR as well as protein levels of
(B) TNF-α and (D) IL-1β by ELISA. The mRNA expression in the sham group is designated as 1
for comparison. Data are expressed as mean ± SE (n = 6–8 per group). *P < 0.05 versus
sham and #P < 0.05 versus vehicle.
Figure 6. Alterations in expression of chemokines and myeloperoxidase activity in the
lungs. The lung tissues of sham, vehicle- and AICAR-treated mice were harvested at 20 h
after CLP for measuring the mRNA levels of (A) KC and (B) MIP-2 by real-time RT-PCR. (C)
Lung myeloperoxidase (MPO) activity was determined spectrophotometrically. The mRNA
expression in the sham group is designated as 1 for comparison. Data are expressed as
mean ± SE (n = 6–8 per group). *P < 0.05 versus sham and #P < 0.05 versus vehicle.
the sympathetic nervous system and re-
lease of norepinephrine which target the
immune cells expressing adrenergic re-
ceptors (49,50); 2) stimulation of the
vagus nerve-mediated cholinergic antiin-
flammatory pathway (23,51,52); and 3)
activation of the hypothalamic-pituitary-
adrenal (HPA) axis for glucocorticoids se-
cretion in response to adrenocorticotropic
hormone and immune suppression
(53,54). However, which pathway(s)
serves as downstream-of-brain AMPK ac-
tivation for modulating the systemic and
peripheral tissue inflammation following
sepsis needs further investigation.
By the same token, Giri et al. present
the evidence that activation of AMPKα2
by AICAR attenuates the LPS-mediated
induction of proinflammatory mediators
in rat primary astrocytes and microglia
cells through inhibiting NF-κB and
C/EBP transcription factors (22). A study
by Bernik et al. demonstrates that intrac-
erebral administration of a tetravalent
guanylhydrazone molecule that inhibited
TNF-α production increases efferent
vagus nerve activity and inhibits inflam-
mation outside the CNS (55). Moreover, it
has been shown that activation of hypo-
thalamic AMPK can prevent LPS-induced
hypoglycemia in mice liver, suggesting
centrally located AMPK in the regulation
of peripheral physiological activities (56).
CONCLUSION
Our results suggest that centrally ad-
ministered AICAR protects against sep-
sis-induced pulmonary injury and apo-
ptosis, and that this protection is
associated with a decrease in circulating
proinflammatory cytokines. Furthermore,
hypothalamic AMPKα2 mediates AICAR
activity to regulate systemic inflamma-
tory response in sepsis. Thus, further un-
derstanding the interaction between the
CNS and systemic activity will provide
another direction for sepsis treatment.
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